CA-ARMIS
12.12.2023 14:01:40 CET | Business Wire | Press release
Armis, the asset intelligence cybersecurity company, today announced that it has been named a leader by analyst group Quadrant Knowledge Solutions in three 2023 SPARK Matrix™ reports for Q4 2023. The reports: SPARK Matrix™: Vulnerability Management, Q4 2023, SPARK Matrix™: Operational Technology (OT) Security, Q4 2023, and SPARK Matrix™: Connected Medical Device Security Solutions, Q4 2023, place three Armis Centrix™ solutions as a Technology Leader with significant customer impact in the areas of Vulnerability Management, Operational Technology Security and Connected Medical Device Security.
“Our Leader position in these three reports is a testament to our commitment to innovation and customer success, and helping organizations see, protect and manage their entire attack surface in real-time,” said Dana Gilboa, Chief Product Officer of Armis. “We are extremely proud that Armis is positioned as a Leader on both the Technology Leader axis and the Customer Impact axis for all three reports. We also want to extend a sincere thank you to the Armis customers who took the time to provide feedback on Armis to Quadrant Knowledge Solutions.”
The SPARK Matrix™ reports analyzed three of Armis’ four core solutions: Vulnerability Management, OT/IoT Security, and Medical Device Security, which are all built on Armis Centrix™, the Armis cyber exposure management platform. Powered by the Armis AI-driven Asset Intelligence Engine, Armis Centrix™ is a seamless, frictionless, cloud-based platform that proactively identifies all cyber asset risks, remediates vulnerabilities, blocks threats and protects the entire attack surface.
SPARK Matrix™ reports analyze the vendor landscape of a technology category and vendor product capabilities. Vendors are evaluated according to their product offerings, market share and customer satisfaction to help CIOs and CISOs make informed technology decisions.
When evaluating why Armis is a technology leader in each of these three core areas, Quadrant Knowledge Solutions shared in its reports:
- Vulnerability Management - “Armis Centrix™ for Vulnerability Prioritization and Remediation bridges critical coverage gaps unattended by Vulnerability assessment tools with aggregation of details such as ownership and location to create full visibility of the attack surface. Armis Centrix™ for Vulnerability Prioritization and Remediation provides holistic visibility into the user’s overall risk and attack surface. The platform also provides the business context of business-critical assets based on their roles. Armis Centrix™ Asset Vulnerability Prioritization and Remediation helps the organization reduce its attack surface by analyzing attributes of devices and overlaying threat intel as a part of the analysis.”
- Operational Technology Security - “Armis Centrix™ for OT/IoT security enables organizations to see and secure OT/IOT networks and physical assets, ensure uptime, and build an effective & comprehensive security strategy. It is powered by Armis’ AI-driven Asset Intelligence Engine and oversees, secures, protects, and manages a wide range of assets in real-time. The cloud-based platform proactively mitigates all cyber asset risks, remediates vulnerabilities, blocks threats, and protects the entire attack surface. Armis for OT/IoT security provides deep visibility to all OT assets as well as to the OT/ICS networks and environment. It allows companies to manage the OT/IT convergence, bridge the IT / OT gap and protect OT networks, monitor connectivity, and track behavior.”
- Connected Medical Device Security - “Armis Centrix™ for Medical Device Security offers features like real-time complete visibility into medical device inventory, information regarding device usage for increasing utilization efficiency, medical device risk assessment based on vulnerabilities, identifying Protected Health Information (PHI) breaches, identifying and remediating threats, and automating security of medical devices. The product is also equipped with an Asset Intelligence Engine with over 20 million device profiles, and the AI-powered Armis Standard Query.”
Learn more about each of these Quadrant Knowledge Solutions reports at the below links:
- SPARK Matrix™: Vulnerability Management, Q4 2023
- SPARK Matrix™: Operational Technology Security, Q4 2023
- SPARK Matrix™: Connected Medical Device Security, Q4 2023
To read our blog, please visit: https://www.armis.com/blog/armis-is-named-a-leader-in-three-2023-quadrant-spark-matrix-reports/
For additional analyst reports sharing insights about Armis Centrix™, go here: https://www.armis.com/resources/?type=analyst-reports
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231212672034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
